Archive
Here you can find the archive of all Press Releases prior to 2018
Filter by date:
Showing 647 press releases before 2018
-
US FDA accepts first biologics license application for AstraZeneca’s durvalumab in bladder cancer
-
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
-
AstraZeneca completes agreement With Cilag GmbH International for rights to Rhinocort Aqua outside the US
-
AstraZeneca takes latest scientific advances in oncology to major US And European congresses
-
AstraZeneca head and neck cancer trials resume new patient enrolment as FDA lifts partial clinical hold
-
MedImmune completes out-licensing agreement with Allergan for MEDI2070
-
Year-to-date and Q3 2016 results
-
AstraZeneca head and neck cancer trials
-
Lynparza Phase III SOLO-2 trial shows significant progression-free survival benefit
-
FDA accepts for review New Drug Application for sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalaemia
Latest articles and press releases
All of our latest press releases and articles are available to explore
Contact us
Gonzalo Viña
Head of Global Media Relations
+44 203 749 5916
Rob Skelding
Director Global Media Relations (Oncology)
+44 203 749 5821
Rebecca Einhorn
Director Global Media Relations (Oncology)
+1 301 398 1802
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 203 749 5906
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 122 334 4690
Jennifer Hursit
Manager Global Media Relations
+44 203 749 5762
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
